Dollars in millions, except per share data
Year Ended December 31,
Net product sales
46,756
46,778
43,778
Alliance and other revenues
1,438
1,522
1,228
Total Revenues
48,194
48,300
45,006
Cost of products sold
(a)
13,936
13,968
10,693
Selling, general and administrative
7,267
8,414
7,772
Research and development
9,951
11,159
9,299
Acquired IPRD
3,721
13,373
Amortization of acquired intangible assets
3,317
8,872
9,047
Other (income)/expense, net
1,158
Total Expenses
38,866
56,679
36,566
Earnings/(Loss) before income taxes
9,328
8,379
8,440
Income tax provision
2,272
Net earnings/(loss)
7,055
8,933
8,040
Noncontrolling Interest
Net earnings/(loss) attributable to BMS
7,054
8,948
8,025
Earnings/(Loss) per common share:
Basic
3.47
4.41
3.88
Diluted
3.46
4.41
3.86
(a)
Excludes amortization of acquired intangible assets.

Question: What was Bristol-Myers Squibb Company's net income in fiscal year 2025?

what was bristol-myers squibb company's net income in fiscal year 2025?

what was net income in fiscal year 2025?

dollars in millions except per share data year ended december 31 net product sales 46756 46778 43778 alliance and other revenues 1438 1522 1228 total revenues 48194 48300 45006 cost of products sold (a) 13936 13968 10693 selling general and administrative 7267 8414 7772 research and development 9951 11159 9299 acquired iprd 3721 13373 amortization of acquired intangible assets 3317 8872 9047 other (income)/expense net 1158 total expenses 38866 56679 36566 earnings/(loss) before income taxes 9328 8379 8440 income tax provision 2272 net earnings/(loss) 7055 8933 8040 noncontrolling interest net earnings/(loss) attributable to bms 7054 8948 8025 earnings/(loss) per common share: basic 3.47 4.41 3.88 diluted 3.46 4.41 3.86 (a) excludes amortization of acquired intangible assets.


Dollars in millions
Year Ended December 31,
Cash Flows From Operating Activities:
Net earnings/(loss)
7,055
8,933
8,040
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
Depreciation and amortization, net
4,011
9,600
9,760
Deferred income taxes
2,089
3,288
Stock-based compensation
Impairment charges
1,098
2,963
Divestiture gains and royalties
1,165
1,119
Acquired IPRD
3,721
13,373
Equity investment (gains)/losses, net
Contingent consideration fair value adjustments
Other adjustments
Changes in operating assets and liabilities:
Receivables
Inventories
Accounts payable
Rebates and discounts
1,484
Income taxes payable
1,260
Other
Net cash provided by operating activities
14,156
15,190
13,860
Cash Flows From Investing Activities:
Sale and maturities of marketable debt securities
1,975
1,122
Purchase of marketable debt securities
2,000
1,774
Proceeds from sales of equity investments
Capital expenditures
1,311
1,248
1,209
Divestiture and other proceeds
1,071
1,099
Acquisition and other payments, net of cash acquired
3,944
21,821
1,169
Net cash provided by/(used in) investing activities
4,132
21,352
2,295
Cash Flows From Financing Activities:
Proceeds from issuance of short-term debt obligations
2,987
Repayments of short-term debt obligations
3,000
Other short-term financing obligations, net
Proceeds from issuance of long-term debt
5,740
12,883
4,455
Repayments of long-term debt
10,940
2,873
3,879
Repurchase of common stock
5,155
Dividends
5,045
4,863
4,744
Stock option proceeds and other, net
Net cash provided by/(used in) financing activities
10,348
5,127
9,416
Effect of exchange rates on cash, cash equivalents and restricted cash
Increase/(decrease) in cash, cash equivalents and restricted cash
1,172
2,194
Cash, cash equivalents and restricted cash at beginning of period
10,347
11,519
9,325
Cash, cash equivalents and restricted cash at end of period
10,218
10,347
11,519
The accompanying notes are an integral part of these consolidated financial statements.
Note 1.
ACCOUNTING POLICIES AND RECENTLY ISSUED ACCOUNTING STANDARDS
Nature of Operations and Basis of Consolidation
Bristol-Myers Squibb Company (“BMS”, or “the Company”) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Question: What was Bristol-Myers Squibb Company's operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was bristol-myers squibb company's operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

dollars in millions year ended december 31 cash flows from operating activities: net earnings/(loss) 7055 8933 8040 adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: depreciation and amortization net 4011 9600 9760 deferred income taxes 2089 3288 stock-based compensation impairment charges 1098 2963 divestiture gains and royalties 1165 1119 acquired iprd 3721 13373 equity investment (gains)/losses net contingent consideration fair value adjustments other adjustments changes in operating assets and liabilities: receivables inventories accounts payable rebates and discounts 1484 income taxes payable 1260 other net cash provided by operating activities 14156 15190 13860 cash flows from investing activities: sale and maturities of marketable debt securities 1975 1122 purchase of marketable debt securities 2000 1774 proceeds from sales of equity investments capital expenditures 1311 1248 1209 divestiture and other proceeds 1071 1099 acquisition and other payments net of cash acquired 3944 21821 1169 net cash provided by/(used in) investing activities 4132 21352 2295 cash flows from financing activities: proceeds from issuance of short-term debt obligations 2987 repayments of short-term debt obligations 3000 other short-term financing obligations net proceeds from issuance of long-term debt 5740 12883 4455 repayments of long-term debt 10940 2873 3879 repurchase of common stock 5155 dividends 5045 4863 4744 stock option proceeds and other net net cash provided by/(used in) financing activities 10348 5127 9416 effect of exchange rates on cash cash equivalents and restricted cash increase/(decrease) in cash cash equivalents and restricted cash 1172 2194 cash cash equivalents and restricted cash at beginning of period 10347 11519 9325 cash cash equivalents and restricted cash at end of period 10218 10347 11519 the accompanying notes are an integral part of these consolidated financial statements. note 1. accounting policies and recently issued accounting standards nature of operations and basis of consolidation bristol-myers squibb company (“bms” or “the company”) is a global biopharmaceutical company whose mission is to discover develop and deliver innovative medicines that help patients prevail over serious diseases.


Question: What was Bristol-Myers Squibb Company's revenue in fiscal year 2025?

what was bristol-myers squibb company's revenue in fiscal year 2025?


Dollars in millions, except share and per share data
December 31,
ASSETS
Current assets:
Cash and cash equivalents
10,209
10,346
Marketable debt securities
Receivables
11,414
10,747
Inventories
2,690
2,557
Other current assets
4,613
5,617
Total Current assets
29,390
29,780
Property, plant and equipment
7,543
7,136
Goodwill
21,754
21,719
Other intangible assets
19,103
23,307
Deferred income taxes
5,378
4,236
Marketable debt securities
Other non-current assets
6,474
6,105
Total Assets
90,038
92,603
LIABILITIES
Current liabilities:
Short-term debt obligations
2,261
2,046
Accounts payable
3,575
3,602
Other current liabilities
17,581
18,126
Total Current liabilities
23,417
23,774
Deferred income taxes
Long-term debt
42,850
47,603
Other non-current liabilities
5,043
4,469
Total Liabilities
71,533
76,215
Commitments and Contingencies (Note 20)
EQUITY
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock, $
convertible series, par value $
per share: Authorized
million shares; issued and outstanding
2,510
in 2025 and
2,868
in 2024, liquidation value of $
per share
Common stock, par value of $
0.10
per share: Authorized
billion shares;
billion issued in 2025 and 2024
Capital in excess of par value of stock
46,387
46,024
Accumulated other comprehensive loss
1,524
1,238
Retained earnings
16,896
14,912
Less cost of treasury stock —
million common shares in 2025 and
million common shares in 2024
43,579
43,655
Total BMS Shareholders’ Equity
18,473
16,335
Noncontrolling interest
Total Equity
18,506
16,388
Total Liabilities and Equity
90,038
92,603
The accompanying notes are an integral part of these consolidated financial statements.
BRISTOL-MYERS SQUIBB COMPANY

Question: What was Bristol-Myers Squibb Company's total assets in fiscal year 2025?

what was bristol-myers squibb company's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

dollars in millions except share and per share data december 31 assets current assets: cash and cash equivalents 10209 10346 marketable debt securities receivables 11414 10747 inventories 2690 2557 other current assets 4613 5617 total current assets 29390 29780 property plant and equipment 7543 7136 goodwill 21754 21719 other intangible assets 19103 23307 deferred income taxes 5378 4236 marketable debt securities other non-current assets 6474 6105 total assets 90038 92603 liabilities current liabilities: short-term debt obligations 2261 2046 accounts payable 3575 3602 other current liabilities 17581 18126 total current liabilities 23417 23774 deferred income taxes long-term debt 42850 47603 other non-current liabilities 5043 4469 total liabilities 71533 76215 commitments and contingencies (note 20) equity bristol-myers squibb company shareholders' equity: preferred stock convertible series par value per share: authorized million shares; issued and outstanding 2510 in 2025 and 2868 in 2024 liquidation value of per share common stock par value of 0.10 per share: authorized billion shares; billion issued in 2025 and 2024 capital in excess of par value of stock 46387 46024 accumulated other comprehensive loss 1524 1238 retained earnings 16896 14912 less cost of treasury stock — million common shares in 2025 and million common shares in 2024 43579 43655 total bms shareholders' equity 18473 16335 noncontrolling interest total equity 18506 16388 total liabilities and equity 90038 92603 the accompanying notes are an integral part of these consolidated financial statements. bristol-myers squibb company


Question: What was Bristol-Myers Squibb Company's gross margin in fiscal year 2025?

what was bristol-myers squibb company's gross margin in fiscal year 2025?

cost of products sold
cost of revenue
cost of sales


Question: What was Bristol-Myers Squibb Company's net margin in fiscal year 2025?

what was bristol-myers squibb company's net margin in fiscal year 2025?


Question: What was Bristol-Myers Squibb Company's operating cash flow margin in fiscal year 2025?

what was bristol-myers squibb company's operating cash flow margin in fiscal year 2025?


Question: By what percentage did Bristol-Myers Squibb Company's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did bristol-myers squibb company's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Bristol-Myers Squibb Company's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did bristol-myers squibb company's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?

dollars in millions except per share data year ended december 31 net product sales 46756 46778 43778 alliance and other revenues 1438 1522 1228 total revenues 48194 48300 45006 cost of products sold (a) 13936 13968 10693 selling general and administrative 7267 8414 7772 research and development 9951 11159 9299 acquired iprd 3721 13373 amortization of acquired intangible assets 3317 8872 9047 other (income)/expense net 1158 total expenses 38866 56679 36566 earnings/(loss) before income taxes 9328 8379 8440 income tax provision 2272 net earnings/(loss) 7055 8933 8040 noncontrolling interest net earnings/(loss) attributable to bms 7054 8948 8025 earnings/(loss) per common share: basic 3.47 4.41 3.88 diluted 3.46 4.41 3.86 (a) excludes amortization of acquired intangible assets.


CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Years ended December 31, 2025, 2024 and 2023
(In millions)
Net income
7,711
4,090
6,717
Other comprehensive (loss) income, net of reclassification adjustments and taxes:
Gains (losses) on foreign currency translation adjustments
(Losses) gains on cash flow hedges
Other
Other comprehensive (loss) income, net of reclassification adjustments and taxes
Comprehensive income
7,519
4,313
6,659
See accompanying notes.
F-5
AMGEN INC.

Question: What was Amgen Inc.'s net income in fiscal year 2025?

what was amgen inc.'s net income in fiscal year 2025?

what was net income in fiscal year 2025?

years ended december 31 2025 2024 and 2023 (in millions) net income 7711 4090 6717 other comprehensive (loss) income net of reclassification adjustments and taxes: gains (losses) on foreign currency translation adjustments (losses) gains on cash flow hedges other other comprehensive (loss) income net of reclassification adjustments and taxes comprehensive income 7519 4313 6659 see accompanying notes. f-5 amgen inc.


Years ended December 31, 2025, 2024 and 2023
(In millions)
Cash flows from operating activities:
Net income
7,711
4,090
6,717
Noncash adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, amortization and other
5,167
5,592
4,071
Impairment of intangible assets
1,200
Stock-based compensation expense
Deferred income taxes
1,228
1,273
(Gains) losses on equity securities
2,064
1,565
Other items, net
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net
2,676
1,015
Inventories
2,532
Other assets
1,267
Accounts payable
Accrued income taxes, net
2,068
1,011
1,031
Long-term tax liabilities
Accrued liabilities
Accrued sales incentives and allowance
2,065
1,194
Other liabilities
Net cash provided by operating activities
9,958
11,490
8,471
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired
26,989
Proceeds from sales of marketable securities
1,123
Proceeds from maturities of marketable securities
Purchases of property, plant and equipment
1,858
1,096
1,112
Other
Net cash used in investing activities
1,943
1,046
26,204
Cash flows from financing activities:
Net proceeds from issuance of debt
27,777
Extinguishment of debt
Repayment of debt
5,000
3,600
1,454
Repurchases of common stock
Dividends paid
5,124
4,832
4,556
Other
Net cash (used in) provided by financing activities
10,859
9,415
21,048
(Decrease) increase in cash and cash equivalents
2,844
1,029
3,315
Cash and cash equivalents at beginning of year
11,973
10,944
7,629
Cash and cash equivalents at end of year
9,129
11,973
10,944
See accompanying notes.
F-8
AMGEN INC.

Question: What was Amgen Inc.'s operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was amgen inc.'s operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

years ended december 31 2025 2024 and 2023 (in millions) cash flows from operating activities: net income 7711 4090 6717 noncash adjustments to reconcile net income to net cash provided by operating activities: depreciation amortization and other 5167 5592 4071 impairment of intangible assets 1200 stock-based compensation expense deferred income taxes 1228 1273 (gains) losses on equity securities 2064 1565 other items net changes in operating assets and liabilities net of acquisitions: trade receivables net 2676 1015 inventories 2532 other assets 1267 accounts payable accrued income taxes net 2068 1011 1031 long-term tax liabilities accrued liabilities accrued sales incentives and allowance 2065 1194 other liabilities net cash provided by operating activities 9958 11490 8471 cash flows from investing activities: cash paid for acquisitions net of cash acquired 26989 proceeds from sales of marketable securities 1123 proceeds from maturities of marketable securities purchases of property plant and equipment 1858 1096 1112 other net cash used in investing activities 1943 1046 26204 cash flows from financing activities: net proceeds from issuance of debt 27777 extinguishment of debt repayment of debt 5000 3600 1454 repurchases of common stock dividends paid 5124 4832 4556 other net cash (used in) provided by financing activities 10859 9415 21048 (decrease) increase in cash and cash equivalents 2844 1029 3315 cash and cash equivalents at beginning of year 11973 10944 7629 cash and cash equivalents at end of year 9129 11973 10944 see accompanying notes. f-8 amgen inc.


Years ended December 31, 2025, 2024 and 2023
(In millions, except per-share data)
Revenues:
Product sales
35,148
32,026
26,910
Other revenues
1,603
1,398
1,280
Total revenues
36,751
33,424
28,190
Operating expenses:
Cost of sales
12,037
12,858
8,451
Research and development
7,272
5,964
4,784
Selling, general and administrative
7,050
7,096
6,179
Other
1,312
Total operating expenses
27,671
26,166
20,293
Operating income
9,080
7,258
7,897
Other income (expense):
Interest expense, net
2,755
3,155
2,875
Other income, net
2,651
2,833
Income before income taxes
8,976
4,609
7,855
Provision for income taxes
1,265
1,138
Net income
7,711
4,090
6,717
Earnings per share:
Basic
14.33
7.62
12.56
Diluted
14.23
7.56
12.49
Weighted-average shares used in the calculation of earnings per share:
Basic
Diluted
See accompanying notes.
F-4
AMGEN INC.

Question: What was Amgen Inc.'s revenue in fiscal year 2025?

revenue from contract with customer excluding assessed tax

what was amgen inc.'s revenue in fiscal year 2025?

years ended december 31 2025 2024 and 2023 (in millions except per-share data) revenues: product sales 35148 32026 26910 other revenues 1603 1398 1280 total revenues 36751 33424 28190 operating expenses: cost of sales 12037 12858 8451 research and development 7272 5964 4784 selling general and administrative 7050 7096 6179 other 1312 total operating expenses 27671 26166 20293 operating income 9080 7258 7897 other income (expense): interest expense net 2755 3155 2875 other income net 2651 2833 income before income taxes 8976 4609 7855 provision for income taxes 1265 1138 net income 7711 4090 6717 earnings per share: basic 14.33 7.62 12.56 diluted 14.23 7.56 12.49 weighted-average shares used in the calculation of earnings per share: basic diluted see accompanying notes. f-4 amgen inc.


December 31, 2025 and 2024
(In millions, except per-share data)
ASSETS
Current assets:
Cash and cash equivalents
9,129
11,973
Trade receivables, net
9,570
6,782
Inventories
6,225
6,998
Other current assets
4,133
3,277
Total current assets
29,057
29,030
Property, plant and equipment, net
7,913
6,543
Intangible assets, net
22,276
27,699
Goodwill
18,680
18,637
Other noncurrent assets
12,660
9,930
Total assets
90,586
91,839
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
2,367
1,908
Accrued liabilities
18,523
17,641
Current portion of long-term debt
4,599
3,550
Total current liabilities
25,489
23,099
Long-term debt
50,005
56,549
Long-term deferred tax liabilities
1,366
1,616
Long-term tax liabilities
2,690
2,349
Other noncurrent liabilities
2,378
2,349
Contingencies and commitments (see Note 20)
Stockholders’ equity:
Common stock and additional paid-in capital; $
0.0001
par value per share;
2,750.0
shares authorized; outstanding—
538.8
shares in 2025 and
536.9
shares in 2024
34,023
33,533
Accumulated deficit
25,107
27,590
Accumulated other comprehensive loss
Total stockholders’ equity
8,658
5,877
Total liabilities and stockholders’ equity
90,586
91,839
See accompanying notes.
F-6
AMGEN INC.

Question: What was Amgen Inc.'s total assets in fiscal year 2025?

what was amgen inc.'s total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

december 31 2025 and 2024 (in millions except per-share data) assets current assets: cash and cash equivalents 9129 11973 trade receivables net 9570 6782 inventories 6225 6998 other current assets 4133 3277 total current assets 29057 29030 property plant and equipment net 7913 6543 intangible assets net 22276 27699 goodwill 18680 18637 other noncurrent assets 12660 9930 total assets 90586 91839 liabilities and stockholders' equity current liabilities: accounts payable 2367 1908 accrued liabilities 18523 17641 current portion of long-term debt 4599 3550 total current liabilities 25489 23099 long-term debt 50005 56549 long-term deferred tax liabilities 1366 1616 long-term tax liabilities 2690 2349 other noncurrent liabilities 2378 2349 contingencies and commitments (see note 20) stockholders' equity: common stock and additional paid-in capital; 0.0001 par value per share; 2750.0 shares authorized; outstanding— 538.8 shares in 2025 and 536.9 shares in 2024 34023 33533 accumulated deficit 25107 27590 accumulated other comprehensive loss total stockholders' equity 8658 5877 total liabilities and stockholders' equity 90586 91839 see accompanying notes. f-6 amgen inc.


Question: What was Amgen Inc.'s gross margin in fiscal year 2025?

what was amgen inc.'s gross margin in fiscal year 2025?


Question: What was Amgen Inc.'s net margin in fiscal year 2025?

what was amgen inc.'s net margin in fiscal year 2025?


Question: What was Amgen Inc.'s operating cash flow margin in fiscal year 2025?

what was amgen inc.'s operating cash flow margin in fiscal year 2025?


Question: By what percentage did Amgen Inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did amgen inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Amgen Inc.'s operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did amgen inc.'s operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did operating income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Amgen Inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did amgen inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


Year Ended December 31,
(in millions, except per share amounts)
Revenues:
Product sales
28,915
28,610
26,934
Royalty, contract and other revenues
Total revenues
29,443
28,754
27,116
Costs and expenses:
Cost of goods sold
6,234
6,251
6,498
Research and development expenses
5,799
5,907
5,718
Acquired in-process research and development expenses
1,024
4,663
1,155
In-process research and development impairments
4,180
Selling, general and administrative expenses
5,774
6,091
6,090
Total costs and expenses
19,421
27,092
19,511
Operating income
10,022
1,662
7,605
Interest expense
1,024
Other (income) expense, net
Income before income taxes
9,796
6,859
Income tax expense
1,286
1,247
Net income
8,510
5,613
Net loss attributable to noncontrolling interest
Net income attributable to Gilead
8,510
5,665
Basic earnings per share attributable to Gilead
6.84
0.38
4.54
Diluted earnings per share attributable to Gilead
6.78
0.38
4.50
Shares used in basic earnings per share attributable to Gilead calculation
1,244
1,247
1,248
Shares used in diluted earnings per share attributable to Gilead calculation
1,255
1,258
See accompanying notes.
GILEAD SCIENCES, INC.

Question: What was Gilead Sciences, Inc.'s net income in fiscal year 2025?

what was gilead sciences inc.'s net income in fiscal year 2025?

what was net income in fiscal year 2025?

year ended december 31 (in millions except per share amounts) revenues: product sales 28915 28610 26934 royalty contract and other revenues total revenues 29443 28754 27116 costs and expenses: cost of goods sold 6234 6251 6498 research and development expenses 5799 5907 5718 acquired in-process research and development expenses 1024 4663 1155 in-process research and development impairments 4180 selling general and administrative expenses 5774 6091 6090 total costs and expenses 19421 27092 19511 operating income 10022 1662 7605 interest expense 1024 other (income) expense net income before income taxes 9796 6859 income tax expense 1286 1247 net income 8510 5613 net loss attributable to noncontrolling interest net income attributable to gilead 8510 5665 basic earnings per share attributable to gilead 6.84 0.38 4.54 diluted earnings per share attributable to gilead 6.78 0.38 4.50 shares used in basic earnings per share attributable to gilead calculation 1244 1247 1248 shares used in diluted earnings per share attributable to gilead calculation 1255 1258 see accompanying notes. gilead sciences inc.


Year Ended December 31,
(in millions)
Operating Activities:
Net income
8,510
5,613
Adjustments to reconcile Net income to Net cash provided by operating activities:
Depreciation expense
Amortization expense
2,390
2,386
2,339
Stock-based compensation expense
Deferred income taxes
1,844
Net (gain) loss from equity securities
Acquired in-process research and development expenses
1,024
4,663
1,155
In-process research and development impairments
4,180
Other, net
Changes in operating assets and liabilities:
Accounts receivable, net
Inventories
1,036
Prepaid expenses and other
Accounts payable
Income tax assets and liabilities, net
2,108
1,768
Accrued and other liabilities
Net cash provided by operating activities
10,019
10,828
8,006
Investing Activities:
Purchases of marketable debt securities
3,939
1,930
Proceeds from sales of marketable debt securities
2,265
Proceeds from maturities of marketable debt securities
1,334
Acquisitions, including in-process research and development, net of cash acquired
1,070
4,840
1,152
Purchases of equity securities
Purchases of property, plant and equipment
Other investing activities, net
Net cash used in investing activities
4,793
3,449
2,265
Financing Activities:
Proceeds from debt financing, net of issuance costs
3,464
1,980
Proceeds from issuances of common stock
Repurchases of common stock under repurchase programs
1,922
1,150
1,000
Repayments of debt and other obligations
1,788
1,970
2,250
Payments of dividends
4,003
3,918
3,809
Other financing activities, net
Net cash used in financing activities
7,745
3,433
5,125
Effect of exchange rate changes on cash and cash equivalents
Net change in cash and cash equivalents
2,428
3,906
Cash and cash equivalents at beginning of period
9,991
6,085
5,412
Cash and cash equivalents at end of period
7,564
9,991
6,085
See accompanying notes.
GILEAD SCIENCES, INC.

Question: What was Gilead Sciences, Inc.'s operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was gilead sciences inc.'s operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

year ended december 31 (in millions) operating activities: net income 8510 5613 adjustments to reconcile net income to net cash provided by operating activities: depreciation expense amortization expense 2390 2386 2339 stock-based compensation expense deferred income taxes 1844 net (gain) loss from equity securities acquired in-process research and development expenses 1024 4663 1155 in-process research and development impairments 4180 other net changes in operating assets and liabilities: accounts receivable net inventories 1036 prepaid expenses and other accounts payable income tax assets and liabilities net 2108 1768 accrued and other liabilities net cash provided by operating activities 10019 10828 8006 investing activities: purchases of marketable debt securities 3939 1930 proceeds from sales of marketable debt securities 2265 proceeds from maturities of marketable debt securities 1334 acquisitions including in-process research and development net of cash acquired 1070 4840 1152 purchases of equity securities purchases of property plant and equipment other investing activities net net cash used in investing activities 4793 3449 2265 financing activities: proceeds from debt financing net of issuance costs 3464 1980 proceeds from issuances of common stock repurchases of common stock under repurchase programs 1922 1150 1000 repayments of debt and other obligations 1788 1970 2250 payments of dividends 4003 3918 3809 other financing activities net net cash used in financing activities 7745 3433 5125 effect of exchange rate changes on cash and cash equivalents net change in cash and cash equivalents 2428 3906 cash and cash equivalents at beginning of period 9991 6085 5412 cash and cash equivalents at end of period 7564 9991 6085 see accompanying notes. gilead sciences inc.


Question: What was Gilead Sciences, Inc.'s revenue in fiscal year 2025?

revenue from contract with customer excluding assessed tax

what was gilead sciences inc.'s revenue in fiscal year 2025?


December 31,
(in millions, except per share amounts)
Assets
Current assets:
Cash and cash equivalents
7,564
9,991
Short-term marketable debt securities
Accounts receivable, net
4,913
4,420
Inventories
1,774
1,710
Prepaid and other current assets
4,024
3,052
Total current assets
18,342
19,173
Property, plant and equipment, net
5,606
5,414
Long-term marketable debt securities
2,974
Intangible assets, net
16,978
19,948
Goodwill
8,314
Deferred tax assets
1,964
2,378
Other long-term assets
4,845
3,769
Total assets
59,023
58,995
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued rebates
4,337
3,892
Current portion of long-term debt, net
2,807
1,815
Other current liabilities
3,953
5,464
Total current liabilities
11,813
12,004
Long-term debt, net
22,129
24,896
Long-term income taxes payable
Deferred tax liabilities
Other long-term liabilities
1,165
1,295
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, par value $
0.001
per share;
shares authorized;
no
ne outstanding
Common stock, par value $
0.001
per share;
5,600
authorized;
1,241
and
1,246
shares issued and outstanding, respectively
Additional paid-in capital
8,932
7,700
Accumulated other comprehensive income
Retained earnings
13,730
11,497
Total Gilead stockholders’ equity
22,703
19,330
Noncontrolling interest
Total stockholders’ equity
22,618
19,246
Total liabilities and stockholders’ equity
59,023
58,995
See accompanying notes.
GILEAD SCIENCES, INC.

Question: What was Gilead Sciences, Inc.'s total assets in fiscal year 2025?

what was gilead sciences inc.'s total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

december 31 (in millions except per share amounts) assets current assets: cash and cash equivalents 7564 9991 short-term marketable debt securities accounts receivable net 4913 4420 inventories 1774 1710 prepaid and other current assets 4024 3052 total current assets 18342 19173 property plant and equipment net 5606 5414 long-term marketable debt securities 2974 intangible assets net 16978 19948 goodwill 8314 deferred tax assets 1964 2378 other long-term assets 4845 3769 total assets 59023 58995 liabilities and stockholders' equity current liabilities: accounts payable accrued rebates 4337 3892 current portion of long-term debt net 2807 1815 other current liabilities 3953 5464 total current liabilities 11813 12004 long-term debt net 22129 24896 long-term income taxes payable deferred tax liabilities other long-term liabilities 1165 1295 commitments and contingencies (note 12) stockholders' equity: preferred stock par value 0.001 per share; shares authorized; no ne outstanding common stock par value 0.001 per share; 5600 authorized; 1241 and 1246 shares issued and outstanding respectively additional paid-in capital 8932 7700 accumulated other comprehensive income retained earnings 13730 11497 total gilead stockholders' equity 22703 19330 noncontrolling interest total stockholders' equity 22618 19246 total liabilities and stockholders' equity 59023 58995 see accompanying notes. gilead sciences inc.


Question: What was Gilead Sciences, Inc.'s gross margin in fiscal year 2025?

what was gilead sciences inc.'s gross margin in fiscal year 2025?


Question: What was Gilead Sciences, Inc.'s net margin in fiscal year 2025?

what was gilead sciences inc.'s net margin in fiscal year 2025?


Question: What was Gilead Sciences, Inc.'s operating cash flow margin in fiscal year 2025?

what was gilead sciences inc.'s operating cash flow margin in fiscal year 2025?


Question: By what percentage did Gilead Sciences, Inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did gilead sciences inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Gilead Sciences, Inc.'s operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did gilead sciences inc.'s operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did operating income change from fiscal year 2024 to fiscal year 2025?

year ended december 31 (in millions except per share amounts) revenues: product sales 28915 28610 26934 royalty contract and other revenues total revenues 29443 28754 27116 costs and expenses: cost of goods sold 6234 6251 6498 research and development expenses 5799 5907 5718 acquired in-process research and development expenses 1024 4663 1155 in-process research and development impairments 4180 selling general and administrative expenses 5774 6091 6090 total costs and expenses 19421 27092 19511 operating income 10022 1662 7605 interest expense 1024 other (income) expense net income before income taxes 9796 6859 income tax expense 1286 1247 net income 8510 5613 net loss attributable to noncontrolling interest net income attributable to gilead 8510 5665 basic earnings per share attributable to gilead 6.84 0.38 4.54 diluted earnings per share attributable to gilead 6.78 0.38 4.50 shares used in basic earnings per share attributable to gilead calculation 1244 1247 1248 shares used in diluted earnings per share attributable to gilead calculation 1255 1258 see accompanying notes. gilead sciences inc.


Question: By what percentage did Gilead Sciences, Inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did gilead sciences inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


Net earnings
3,246
2,993
3,165
Other comprehensive income (loss), net of tax
Marketable securities
Pension plans
Unrealized gains (losses) on designated hedges
Financial statement translation
Total other comprehensive income (loss), net of tax
Comprehensive income
2,852
3,116
2,970
See accompanying notes to Consolidated Financial Statements.
Dollar amounts in millions except per share amounts or as otherwise specified.
STRYKER CORPORATION
FORM 10-K
Stryker Corporation and Subsidiaries

Question: What was Stryker Corporation's net income in fiscal year 2025?

what was net income in fiscal year 2025?

what was stryker corporation's net income in fiscal year 2025?

net earnings 3246 2993 3165 other comprehensive income (loss) net of tax marketable securities pension plans unrealized gains (losses) on designated hedges financial statement translation total other comprehensive income (loss) net of tax comprehensive income 2852 3116 2970 see accompanying notes to consolidated financial statements. dollar amounts in millions except per share amounts or as otherwise specified. stryker corporation form 10-k stryker corporation and subsidiaries


Operating activities
Net earnings
3,246
2,993
3,165
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation
Amortization of intangible assets
Goodwill and other impairments
Share-based compensation
Sale of inventory stepped up to fair value at acquisition
Deferred income tax (benefit) expense
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Accounts payable
Accrued expenses and other liabilities
Income taxes
Other, net
Net cash provided by operating activities
5,044
4,242
3,711
Investing activities
Acquisitions, net of cash acquired
4,960
1,628
Proceeds/(Purchases) of short-term investments
Purchases of property, plant and equipment
Proceeds from the sale of the Spinal Implants business
Other investing, net
Net cash used in investing activities
4,866
3,000
Financing activities
Proceeds (payments) on short-term borrowings, net
Proceeds from issuance of long-term debt
2,979
3,011
1,241
Payments on long-term debt
1,400
2,039
2,058
Payments of dividends
1,284
1,219
1,139
Cash paid for taxes from withheld shares
Other financing, net
Net cash provided by (used in) financing activities
1,594
Effect of exchange rate changes on cash and cash equivalents
Change in cash and cash equivalents
1,127
Cash and cash equivalents at beginning of year
3,652
2,971
1,844
Cash and cash equivalents at end of year
4,011
3,652
2,971
Supplemental cash flow disclosure:
Cash paid for income taxes, net of refunds
1,002
Cash paid for interest on debt
See accompanying notes to Consolidated Financial Statements.
Dollar amounts in millions except per share amounts or as otherwise specified.
STRYKER CORPORATION
FORM 10-K

Question: What was Stryker Corporation's operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was operating cash flow in fiscal year 2025?

what was stryker corporation's operating cash flow in fiscal year 2025?

operating activities net earnings 3246 2993 3165 adjustments to reconcile net earnings to net cash provided by operating activities: depreciation amortization of intangible assets goodwill and other impairments share-based compensation sale of inventory stepped up to fair value at acquisition deferred income tax (benefit) expense changes in operating assets and liabilities: accounts receivable inventories accounts payable accrued expenses and other liabilities income taxes other net net cash provided by operating activities 5044 4242 3711 investing activities acquisitions net of cash acquired 4960 1628 proceeds/(purchases) of short-term investments purchases of property plant and equipment proceeds from the sale of the spinal implants business other investing net net cash used in investing activities 4866 3000 financing activities proceeds (payments) on short-term borrowings net proceeds from issuance of long-term debt 2979 3011 1241 payments on long-term debt 1400 2039 2058 payments of dividends 1284 1219 1139 cash paid for taxes from withheld shares other financing net net cash provided by (used in) financing activities 1594 effect of exchange rate changes on cash and cash equivalents change in cash and cash equivalents 1127 cash and cash equivalents at beginning of year 3652 2971 1844 cash and cash equivalents at end of year 4011 3652 2971 supplemental cash flow disclosure: cash paid for income taxes net of refunds 1002 cash paid for interest on debt see accompanying notes to consolidated financial statements. dollar amounts in millions except per share amounts or as otherwise specified. stryker corporation form 10-k


Net sales
25,116
22,595
20,498
Cost of sales
9,051
8,155
7,440
Gross profit
16,065
14,440
13,058
Research, development and engineering expenses
1,623
1,466
1,388
Selling, general and administrative expenses
8,651
7,685
7,111
Amortization of intangible assets
Goodwill and other impairments
Total operating expenses
11,176
10,751
9,170
Operating income
4,889
3,689
3,888
Interest expense
Other income
Earnings before income taxes
4,514
3,492
3,673
Income taxes
1,268
Net earnings
3,246
2,993
3,165
Net earnings per share of common stock:
Basic
8.49
7.86
8.34
Diluted
8.40
7.76
8.25
Weighted-average shares outstanding (in millions):
Basic
382.2
381.0
379.6
Effect of dilutive employee stock compensation
Diluted
386.5
385.6
383.7

Question: What was Stryker Corporation's revenue in fiscal year 2025?

what was stryker corporation's revenue in fiscal year 2025?

net sales 25116 22595 20498 cost of sales 9051 8155 7440 gross profit 16065 14440 13058 research development and engineering expenses 1623 1466 1388 selling general and administrative expenses 8651 7685 7111 amortization of intangible assets goodwill and other impairments total operating expenses 11176 10751 9170 operating income 4889 3689 3888 interest expense other income earnings before income taxes 4514 3492 3673 income taxes 1268 net earnings 3246 2993 3165 net earnings per share of common stock: basic 8.49 7.86 8.34 diluted 8.40 7.76 8.25 weighted-average shares outstanding (in millions): basic 382.2 381.0 379.6 effect of dilutive employee stock compensation diluted 386.5 385.6 383.7


2,265
Segment operating income
7,492
6,595
5,735
Items not allocated to segments:
Corporate and Other
Inventory stepped up to fair value
Acquisition and integration-related charges
Amortization of intangible assets
Structural optimization and other special
charges
Goodwill and other impairments
Medical device regulation
Recall-related matters
Regulatory and legal matters
Consolidated operating income
4,889
3,689
3,888
Segment Assets and Capital Spending
Assets:
MedSurg and Neurotechnology
27,647
23,115
Orthopaedics
18,641
18,507
Total segment assets
46,288
41,622
Corporate and Other
1,556
1,349
Total assets
47,844
42,971
Purchases of property, plant and
equipment:
Orthopaedics
MedSurg and Neurotechnology
Total segment purchases of property,
plant and equipment
Corporate and Other
Total purchases of property, plant and
equipment
We measure the financial results of our reportable segments
using an internal performance measure that excludes acquisition
and integration-related charges, structural optimization and other
special charges, goodwill and other impairments, reserves for
certain product recall matters and reserves for certain legal and
regulatory matters. Identifiable assets are those assets used
exclusively in the operations of each business segment or
allocated when used jointly. Corporate assets are principally
Dollar amounts in millions except per share amounts or as otherwise specified.
STRYKER CORPORATION
FORM 10-K
property, plant and equipment and noncurrent assets.
The countries in which we have local revenue generating
operations have been combined into the following geographic
areas: the United States; Europe, Middle East, Africa; Asia
Pacific; and other foreign countries, which include Canada and
countries in the Latin American region. Net sales are reported
based on the geographic area of the Stryker location where the
sales to the customer originated.
Geographic Information
Net Sales
Net Property, Plant
and Equipment
United States
19,006
16,943
15,257
2,084
1,997
Europe, Middle
East, Africa
3,181
2,897
2,618
1,562
1,260
Asia Pacific
2,164
2,020
1,946
Other countries
Total
25,116
22,595
20,498
3,876
3,448
NOTE 15 -
ASSET IMPAIRMENTS
During
and
we recorded impairment charges of
and
to write off long-lived and intangible assets
excluding long-lived assets held for sale which included charges
related to certain product line exits
OTE 16 -
SALE OF SPINAL IMPLANTS BUSINESS
During the fourth quarter 2024 management committed to a plan
to sell certain assets associated with the Spinal Implants
business (disposal group) and such assets were classified as
held for sale beginning November 2024. As a result we recorded
a valuation allowance of
to record the disposal group at its

Question: What was Stryker Corporation's total assets in fiscal year 2025?

what was stryker corporation's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

2265 segment operating income 7492 6595 5735 items not allocated to segments: corporate and other inventory stepped up to fair value acquisition and integration-related charges amortization of intangible assets structural optimization and other special charges goodwill and other impairments medical device regulation recall-related matters regulatory and legal matters consolidated operating income 4889 3689 3888 segment assets and capital spending assets: medsurg and neurotechnology 27647 23115 orthopaedics 18641 18507 total segment assets 46288 41622 corporate and other 1556 1349 total assets 47844 42971 purchases of property plant and equipment: orthopaedics medsurg and neurotechnology total segment purchases of property plant and equipment corporate and other total purchases of property plant and equipment we measure the financial results of our reportable segments using an internal performance measure that excludes acquisition and integration-related charges structural optimization and other special charges goodwill and other impairments reserves for certain product recall matters and reserves for certain legal and regulatory matters. identifiable assets are those assets used exclusively in the operations of each business segment or allocated when used jointly. corporate assets are principally dollar amounts in millions except per share amounts or as otherwise specified. stryker corporation form 10-k property plant and equipment and noncurrent assets. the countries in which we have local revenue generating operations have been combined into the following geographic areas: the united states; europe middle east africa; asia pacific; and other foreign countries which include canada and countries in the latin american region. net sales are reported based on the geographic area of the stryker location where the sales to the customer originated. geographic information net sales net property plant and equipment united states 19006 16943 15257 2084 1997 europe middle east africa 3181 2897 2618 1562 1260 asia pacific 2164 2020 1946 other countries total 25116 22595 20498 3876 3448 note 15 - asset impairments during and we recorded impairment charges of and to write off long-lived and intangible assets excluding long-lived assets held for sale which included charges related to certain product line exits ote 16 - sale of spinal implants business during the fourth quarter 2024 management committed to a plan to sell certain assets associated with the spinal implants business (disposal group) and such assets were classified as held for sale beginning november 2024. as a result we recorded a valuation allowance of to record the disposal group at its


Question: What was Stryker Corporation's gross margin in fiscal year 2025?

what was stryker corporation's gross margin in fiscal year 2025?


Question: What was Stryker Corporation's net margin in fiscal year 2025?

what was stryker corporation's net margin in fiscal year 2025?


Question: What was Stryker Corporation's operating cash flow margin in fiscal year 2025?

what was stryker corporation's operating cash flow margin in fiscal year 2025?


Question: By what percentage did Stryker Corporation's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did stryker corporation's net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Stryker Corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did stryker corporation's operating income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Stryker Corporation's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did stryker corporation's revenue change from fiscal year 2024 to fiscal year 2025?


(IN MILLIONS, EXCEPT PER SHARE AMOUNTS)
Year Ended December 31,
Revenue:
Product
8,492.6
7,045.0
5,956.3
Service
1,572.1
1,307.1
1,167.8
Total revenue
10,064.7
8,352.1
7,124.1
Cost of revenue:
Product
2,866.1
2,313.1
2,041.8
Service
556.3
404.8
352.8
Total cost of revenue
3,422.4
2,717.9
2,394.6
Gross profit
6,642.3
5,634.2
4,729.5
Operating expenses:
Selling, general and administrative
2,385.0
2,140.0
1,963.9
Research and development
1,311.8
1,145.3
998.8
Total operating expenses
3,696.8
3,285.3
2,962.7
Income from operations
2,945.5
2,348.9
1,766.8
Interest and other income, net
365.9
324.9
192.1
Income before taxes
3,311.4
2,673.8
1,958.9
Income tax expense
434.8
336.3
141.6
Net income
2,876.6
2,337.5
1,817.3
Less: net income attributable to noncontrolling interest in joint venture
20.6
14.9
19.3
Net income attributable to Intuitive Surgical, Inc.
2,856.0
2,322.6
1,798.0
Net income per share attributable to Intuitive Surgical, Inc.:
Basic
8.00
6.54
5.12
Diluted
7.87
6.42
5.03
Shares used in computing net income per share attributable to Intuitive Surgical, Inc.:
Basic
356.9
355.2
351.2
Diluted
362.7
362.0
357.4
The accompanying notes are an integral part of these Consolidated Financial Statements.
INTUITIVE SURGICAL, INC.

Question: What was Intuitive Surgical, Inc.'s net income in fiscal year 2025?

what was intuitive surgical inc.'s net income in fiscal year 2025?

what was net income in fiscal year 2025?

(in millions except per share amounts) year ended december 31 revenue: product 8492.6 7045.0 5956.3 service 1572.1 1307.1 1167.8 total revenue 10064.7 8352.1 7124.1 cost of revenue: product 2866.1 2313.1 2041.8 service 556.3 404.8 352.8 total cost of revenue 3422.4 2717.9 2394.6 gross profit 6642.3 5634.2 4729.5 operating expenses: selling general and administrative 2385.0 2140.0 1963.9 research and development 1311.8 1145.3 998.8 total operating expenses 3696.8 3285.3 2962.7 income from operations 2945.5 2348.9 1766.8 interest and other income net 365.9 324.9 192.1 income before taxes 3311.4 2673.8 1958.9 income tax expense 434.8 336.3 141.6 net income 2876.6 2337.5 1817.3 less: net income attributable to noncontrolling interest in joint venture 20.6 14.9 19.3 net income attributable to intuitive surgical inc. 2856.0 2322.6 1798.0 net income per share attributable to intuitive surgical inc.: basic 8.00 6.54 5.12 diluted 7.87 6.42 5.03 shares used in computing net income per share attributable to intuitive surgical inc.: basic 356.9 355.2 351.2 diluted 362.7 362.0 357.4 the accompanying notes are an integral part of these consolidated financial statements. intuitive surgical inc.


(IN MILLIONS)
Year Ended December 31,
Operating activities:
Net income
2,876.6
2,337.5
1,817.3
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and loss on disposal of property, plant, and equipment, net
614.7
445.3
401.6
Amortization of intangible and other assets
62.4
54.4
53.2
Gain on sale of business
(Gain) loss on investments and (accretion) amortization of investment discounts and premiums, net
57.2
43.3
Deferred income taxes
19.1
135.3
280.8
Share-based compensation expense
788.2
676.8
592.8
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable
301.7
95.9
186.3
Inventory
1,063.4
830.0
712.5
Prepaids and other assets
187.1
231.8
24.2
Accounts payable
57.9
41.7
Accrued compensation and employee benefits
112.7
99.3
34.8
Deferred revenue
75.2
31.2
53.4
Other liabilities
34.1
108.3
32.9
Net cash provided by operating activities
3,030.5
2,415.0
1,813.8
Investing activities:
Purchases of investments
1,215.9
5,139.6
2,207.4
Proceeds from sales of investments
259.9
100.2
230.3
Proceeds from maturities of investments
2,175.5
2,878.8
2,690.1
Purchases of property, plant, and equipment
539.8
1,111.2
1,064.2
Acquisition of businesses, net of cash, and intellectual property and other investing activities
13.9
Net cash provided by (used in) investing activities
665.8
3,272.8
360.1
Financing activities:
Proceeds from issuance of common stock relating to employee stock plans
350.3
429.4
296.3
Taxes paid related to net share settlement of equity awards
419.1
270.0
164.7
Repurchases of common stock
2,295.3
416.3
Cash dividends paid by joint venture to noncontrolling interest
Payment of deferred purchase consideration
Net cash provided by (used in) financing activities
2,364.1
150.9
287.6
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
12.8
Net increase (decrease) in cash, cash equivalents, and restricted cash
1,345.0
707.7
1,169.4
Cash, cash equivalents, and restricted cash, beginning of year
2,062.4
2,770.1
1,600.7
Cash, cash equivalents, and restricted cash, end of year
3,407.4
2,062.4
2,770.1
The accompanying notes are an integral part of these Consolidated Financial Statements.
INTUITIVE SURGICAL, INC.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
In this report, “Intuitive,” the “Company,” “we,” “us,” and “our” refer to Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries.
NOTE 1.
DESCRIPTION OF THE BUSINESS

Question: What was Intuitive Surgical, Inc.'s operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was intuitive surgical inc.'s operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

(in millions) year ended december 31 operating activities: net income 2876.6 2337.5 1817.3 adjustments to reconcile net income to net cash provided by operating activities: depreciation and loss on disposal of property plant and equipment net 614.7 445.3 401.6 amortization of intangible and other assets 62.4 54.4 53.2 gain on sale of business (gain) loss on investments and (accretion) amortization of investment discounts and premiums net 57.2 43.3 deferred income taxes 19.1 135.3 280.8 share-based compensation expense 788.2 676.8 592.8 changes in operating assets and liabilities net of effects of acquisitions: accounts receivable 301.7 95.9 186.3 inventory 1063.4 830.0 712.5 prepaids and other assets 187.1 231.8 24.2 accounts payable 57.9 41.7 accrued compensation and employee benefits 112.7 99.3 34.8 deferred revenue 75.2 31.2 53.4 other liabilities 34.1 108.3 32.9 net cash provided by operating activities 3030.5 2415.0 1813.8 investing activities: purchases of investments 1215.9 5139.6 2207.4 proceeds from sales of investments 259.9 100.2 230.3 proceeds from maturities of investments 2175.5 2878.8 2690.1 purchases of property plant and equipment 539.8 1111.2 1064.2 acquisition of businesses net of cash and intellectual property and other investing activities 13.9 net cash provided by (used in) investing activities 665.8 3272.8 360.1 financing activities: proceeds from issuance of common stock relating to employee stock plans 350.3 429.4 296.3 taxes paid related to net share settlement of equity awards 419.1 270.0 164.7 repurchases of common stock 2295.3 416.3 cash dividends paid by joint venture to noncontrolling interest payment of deferred purchase consideration net cash provided by (used in) financing activities 2364.1 150.9 287.6 effect of exchange rate changes on cash cash equivalents and restricted cash 12.8 net increase (decrease) in cash cash equivalents and restricted cash 1345.0 707.7 1169.4 cash cash equivalents and restricted cash beginning of year 2062.4 2770.1 1600.7 cash cash equivalents and restricted cash end of year 3407.4 2062.4 2770.1 the accompanying notes are an integral part of these consolidated financial statements. intuitive surgical inc. notes to the consolidated financial statements in this report “intuitive” the “company” “we” “us” and “our” refer to intuitive surgical inc. and its wholly and majority-owned subsidiaries. note 1. description of the business


Question: What was Intuitive Surgical, Inc.'s gross margin in fiscal year 2025?

what was intuitive surgical inc.'s gross margin in fiscal year 2025?


Question: What was Intuitive Surgical, Inc.'s net margin in fiscal year 2025?

what was intuitive surgical inc.'s net margin in fiscal year 2025?


Question: What was Intuitive Surgical, Inc.'s operating cash flow margin in fiscal year 2025?

what was intuitive surgical inc.'s operating cash flow margin in fiscal year 2025?


Question: By what percentage did Intuitive Surgical, Inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did intuitive surgical inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Intuitive Surgical, Inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did intuitive surgical inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

revenue from contract with customer excluding assessed tax


For the Years Ended December 31,
In millions, except per share amounts
Revenues:
Products
249,908
231,521
245,138
Premiums
134,751
122,896
99,192
Services
15,175
16,239
12,293
Net investment income
2,233
2,153
1,153
Total revenues
402,067
372,809
357,776
Operating costs:
Cost of products sold
221,167
206,287
217,098
Health care costs
125,538
115,121
86,247
Operating expenses
44,977
41,706
39,832
Goodwill impairment
5,725
Restructuring charges
1,179
Loss on assets held for sale
Total operating costs
397,407
364,293
344,033
Operating income
4,660
8,516
13,743
Interest expense
3,119
2,958
2,658
Gain on early extinguishment of debt
Gain on deconsolidation of subsidiary
Other income
Income before income tax provision
2,136
6,148
11,173
Income tax provision
1,562
2,805
Net income
1,728
4,586
8,368
Net (income) loss attributable to noncontrolling interests
Net income attributable to CVS Health
1,768
4,614
8,344
Net income per share attributable to CVS Health:
Basic
1.40
3.67
6.49
Diluted
1.39
3.66
6.47
Weighted average shares outstanding:
Basic
1,267
1,259
1,285
Diluted
1,271
1,262
1,290
See accompanying notes to consolidated financial statements.

Question: What was CVS Health Corporation's net income in fiscal year 2025?

what was cvs health corporation's net income in fiscal year 2025?

for the years ended december 31 in millions except per share amounts revenues: products 249908 231521 245138 premiums 134751 122896 99192 services 15175 16239 12293 net investment income 2233 2153 1153 total revenues 402067 372809 357776 operating costs: cost of products sold 221167 206287 217098 health care costs 125538 115121 86247 operating expenses 44977 41706 39832 goodwill impairment 5725 restructuring charges 1179 loss on assets held for sale total operating costs 397407 364293 344033 operating income 4660 8516 13743 interest expense 3119 2958 2658 gain on early extinguishment of debt gain on deconsolidation of subsidiary other income income before income tax provision 2136 6148 11173 income tax provision 1562 2805 net income 1728 4586 8368 net (income) loss attributable to noncontrolling interests net income attributable to cvs health 1768 4614 8344 net income per share attributable to cvs health: basic 1.40 3.67 6.49 diluted 1.39 3.66 6.47 weighted average shares outstanding: basic 1267 1259 1285 diluted 1271 1262 1290 see accompanying notes to consolidated financial statements.


For the Years Ended December 31,
In millions
Cash flows from operating activities:
Cash receipts from customers
389,128
357,995
345,464
Cash paid for inventory, prescriptions dispensed and health services rendered
216,493
197,726
208,848
Insurance benefits paid
121,238
109,464
84,097
Cash paid to other suppliers and employees
37,570
38,821
34,735
Interest and investment income received
1,969
1,735
1,584
Interest paid
2,991
2,909
2,418
Income taxes paid
2,166
1,703
3,524
Net cash provided by operating activities
10,639
9,107
13,426
Cash flows from investing activities:
Proceeds from sales and maturities of investments
12,383
10,353
7,729
Purchases of investments
15,012
15,191
9,043
Purchases of property and equipment
2,832
2,781
3,031
Acquisitions (net of cash and restricted cash acquired)
16,612
Other
Net cash used in investing activities
5,871
7,613
20,889
Cash flows from financing activities:
Commercial paper borrowings (repayments), net
2,119
1,919
Proceeds from issuance of short-term loan
5,000
Repayment of short-term loan
5,000
Proceeds from issuance of long-term debt
3,969
7,913
10,898
Repayments of long-term debt
3,629
4,773
3,166
Repurchase of common stock
3,023
2,012
Dividends paid
3,397
3,373
3,132
Proceeds from exercise of stock options
Payments for taxes related to net share settlement of equity awards
Other
Net cash provided by (used in) financing activities
4,940
1,135
2,683
Net increase (decrease) in cash, cash equivalents and restricted cash
4,780
Cash, cash equivalents and restricted cash at the beginning of the period
8,884
8,525
13,305
Cash, cash equivalents and restricted cash at the end of the period
8,712
8,884
8,525

Question: What was CVS Health Corporation's operating cash flow in fiscal year 2025?

what was cvs health corporation's operating cash flow in fiscal year 2025?

for the years ended december 31 in millions cash flows from operating activities: cash receipts from customers 389128 357995 345464 cash paid for inventory prescriptions dispensed and health services rendered 216493 197726 208848 insurance benefits paid 121238 109464 84097 cash paid to other suppliers and employees 37570 38821 34735 interest and investment income received 1969 1735 1584 interest paid 2991 2909 2418 income taxes paid 2166 1703 3524 net cash provided by operating activities 10639 9107 13426 cash flows from investing activities: proceeds from sales and maturities of investments 12383 10353 7729 purchases of investments 15012 15191 9043 purchases of property and equipment 2832 2781 3031 acquisitions (net of cash and restricted cash acquired) 16612 other net cash used in investing activities 5871 7613 20889 cash flows from financing activities: commercial paper borrowings (repayments) net 2119 1919 proceeds from issuance of short-term loan 5000 repayment of short-term loan 5000 proceeds from issuance of long-term debt 3969 7913 10898 repayments of long-term debt 3629 4773 3166 repurchase of common stock 3023 2012 dividends paid 3397 3373 3132 proceeds from exercise of stock options payments for taxes related to net share settlement of equity awards other net cash provided by (used in) financing activities 4940 1135 2683 net increase (decrease) in cash cash equivalents and restricted cash 4780 cash cash equivalents and restricted cash at the beginning of the period 8884 8525 13305 cash cash equivalents and restricted cash at the end of the period 8712 8884 8525


At December 31,
In millions, except per share amounts
Assets:
Cash and cash equivalents
8,453
8,586
Investments
2,145
2,407
Accounts receivable, net
39,779
36,469
Inventories
19,246
18,107
Other current assets
5,091
3,076
Total current assets
74,714
68,645
Long-term investments
32,669
28,934
Property and equipment, net
13,083
12,993
Operating lease right-of-use assets
14,973
15,944
Goodwill
85,478
91,272
Intangible assets, net
25,508
27,323
Separate accounts assets
1,994
3,311
Other assets
5,119
4,793
Total assets
253,538
253,215
Liabilities:
Accounts payable
17,641
15,892
Pharmacy claims and discounts payable
26,344
24,166
Health care costs payable
15,399
15,064
Accrued expenses and other current liabilities
22,387
20,810
Other insurance liabilities
1,116
1,183
Current portion of operating lease liabilities
1,737
1,751
Short-term debt
2,119
Current portion of long-term debt
4,068
3,624
Total current liabilities
88,692
84,609
Long-term operating lease liabilities
13,643
14,899
Long-term debt
60,502
60,527
Deferred income taxes
3,832
3,806
Separate accounts liabilities
1,994
3,311
Other long-term insurance liabilities
4,716
4,902
Other long-term liabilities
4,777
5,431
Total liabilities
178,156
177,485
Commitments and contingencies (Note 18)
Shareholders’ equity:
Preferred stock, par value $
0.01
shares authorized;
none
issued or outstanding
Common stock, par value $
0.01
3,200
shares authorized;
1,787
shares issued and
1,271
shares outstanding at December 31, 2025 and
1,778
shares issued and
1,260
shares outstanding at December 31, 2024 and capital surplus
50,402
49,661
Treasury stock, at cost:
and
shares at December 31, 2025 and 2024
36,790
36,818
Retained earnings
61,196
62,837
Accumulated other comprehensive income (loss)
Total CVS Health shareholders’ equity
75,214
75,560
Noncontrolling interests
Total shareholders’ equity
75,382
75,730
Total liabilities and shareholders’ equity
253,538
253,215
See accompanying notes to consolidated financial statements.

Question: What was CVS Health Corporation's total assets in fiscal year 2025?

what was cvs health corporation's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

at december 31 in millions except per share amounts assets: cash and cash equivalents 8453 8586 investments 2145 2407 accounts receivable net 39779 36469 inventories 19246 18107 other current assets 5091 3076 total current assets 74714 68645 long-term investments 32669 28934 property and equipment net 13083 12993 operating lease right-of-use assets 14973 15944 goodwill 85478 91272 intangible assets net 25508 27323 separate accounts assets 1994 3311 other assets 5119 4793 total assets 253538 253215 liabilities: accounts payable 17641 15892 pharmacy claims and discounts payable 26344 24166 health care costs payable 15399 15064 accrued expenses and other current liabilities 22387 20810 other insurance liabilities 1116 1183 current portion of operating lease liabilities 1737 1751 short-term debt 2119 current portion of long-term debt 4068 3624 total current liabilities 88692 84609 long-term operating lease liabilities 13643 14899 long-term debt 60502 60527 deferred income taxes 3832 3806 separate accounts liabilities 1994 3311 other long-term insurance liabilities 4716 4902 other long-term liabilities 4777 5431 total liabilities 178156 177485 commitments and contingencies (note 18) shareholders' equity: preferred stock par value 0.01 shares authorized; none issued or outstanding common stock par value 0.01 3200 shares authorized; 1787 shares issued and 1271 shares outstanding at december 31 2025 and 1778 shares issued and 1260 shares outstanding at december 31 2024 and capital surplus 50402 49661 treasury stock at cost: and shares at december 31 2025 and 2024 36790 36818 retained earnings 61196 62837 accumulated other comprehensive income (loss) total cvs health shareholders' equity 75214 75560 noncontrolling interests total shareholders' equity 75382 75730 total liabilities and shareholders' equity 253538 253215 see accompanying notes to consolidated financial statements.


Question: By what percentage did CVS Health Corporation's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did cvs health corporation's net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did CVS Health Corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did cvs health corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did operating income change from fiscal year 2024 to fiscal year 2025?


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2025, 2024 and 2023 (dollars and shares in millions, except per share amounts):
Net income attributable to HCA Healthcare, Inc.
6,784
5,760
5,242
Weighted average common shares outstanding
236.413
258.603
272.404
Effect of dilutive incremental shares
3.082
3.203
4.008
Shares used for diluted earnings per share
239.495
261.806
276.412
Earnings per share:
Basic earnings per share
28.70
22.27
19.25
Diluted earnings per share
28.33
22.00
18.97
F-
HCA HEALTHCARE, INC.

Question: What was HCA Healthcare, Inc.'s net income in fiscal year 2025?

what was hca healthcare inc.'s net income in fiscal year 2025?

what was net income in fiscal year 2025?

2025 2024 and 2023 (dollars and shares in millions except per share amounts): net income attributable to hca healthcare inc. 6784 5760 5242 weighted average common shares outstanding 236.413 258.603 272.404 effect of dilutive incremental shares 3.082 3.203 4.008 shares used for diluted earnings per share 239.495 261.806 276.412 earnings per share: basic earnings per share 28.70 22.27 19.25 diluted earnings per share 28.33 22.00 18.97 f- hca healthcare inc.


FOR THE YEARS ENDED DECEMBER 31, 2025, 2024 AND 2023
(Dollars in millions)
Cash flows from operating activities:
Net income
7,782
6,657
6,091
Adjustments to reconcile net income to net cash provided by
operating activities:
Increase (decrease) in cash from operating assets and liabilities:
Accounts receivable
Inventories and other assets
Accounts payable and accrued expenses
Depreciation and amortization
3,523
3,312
3,077
Income taxes
Losses (gains) on sales of facilities
Amortization of debt issuance costs and discounts
Share-based compensation
Other
Net cash provided by operating activities
12,636
10,514
9,431
Cash flows from investing activities:
Purchase of property and equipment
4,944
4,875
4,744
Acquisition of hospitals and health care entities
Sales of hospitals and health care entities
Change in investments
Other
Net cash used in investing activities
4,988
4,933
5,317
Cash flows from financing activities:
Issuances of long-term debt
8,474
7,495
3,224
Net change in short-term borrowings and revolving credit facilities
2,202
1,880
1,020
Repayment of long-term debt
7,389
2,410
Distributions to noncontrolling interests
Payment of debt issuance costs
Payment of dividends
Repurchase of common stock
10,067
6,042
3,811
Other
Net cash used in financing activities
8,550
4,582
4,094
Effect of exchange rate changes on cash and cash equivalents
Change in cash and cash equivalents
Cash and cash equivalents at beginning of period
1,933
Cash and cash equivalents at end of period
1,040
1,933
Interest payments
2,207
1,938
1,892
Income tax payments, net
1,740
1,844
1,386
The accompanying notes are an integral part of the consolidated financial statements.
F-
HCA HEALTHCARE, INC.

Question: What was HCA Healthcare, Inc.'s operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was hca healthcare inc.'s operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

for the years ended december 31 2025 2024 and 2023 (dollars in millions) cash flows from operating activities: net income 7782 6657 6091 adjustments to reconcile net income to net cash provided by operating activities: increase (decrease) in cash from operating assets and liabilities: accounts receivable inventories and other assets accounts payable and accrued expenses depreciation and amortization 3523 3312 3077 income taxes losses (gains) on sales of facilities amortization of debt issuance costs and discounts share-based compensation other net cash provided by operating activities 12636 10514 9431 cash flows from investing activities: purchase of property and equipment 4944 4875 4744 acquisition of hospitals and health care entities sales of hospitals and health care entities change in investments other net cash used in investing activities 4988 4933 5317 cash flows from financing activities: issuances of long-term debt 8474 7495 3224 net change in short-term borrowings and revolving credit facilities 2202 1880 1020 repayment of long-term debt 7389 2410 distributions to noncontrolling interests payment of debt issuance costs payment of dividends repurchase of common stock 10067 6042 3811 other net cash used in financing activities 8550 4582 4094 effect of exchange rate changes on cash and cash equivalents change in cash and cash equivalents cash and cash equivalents at beginning of period 1933 cash and cash equivalents at end of period 1040 1933 interest payments 2207 1938 1892 income tax payments net 1740 1844 1386 the accompanying notes are an integral part of the consolidated financial statements. f- hca healthcare inc.


HCA HEALTHCARE, INC.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Operating Results Summary
The following are comparative summaries of operating results and certain operating data for the years ended December 31, 2025, 2024 and 2023 (dollars in millions):
Amount
Ratio
Amount
Ratio
Amount
Ratio
Revenues
75,600
100.0
70,603
100.0
64,968
100.0
Salaries and benefits
32,859
43.5
31,170
44.1
29,487
45.4
Supplies
11,367
15.0
10,755
15.2
9,902
15.2
Other operating expenses
15,886
21.0
14,819
21.0
12,875
19.8
Equity in earnings of affiliates
(78
(23
(22
Depreciation and amortization
3,523
3,312
3,077
Interest expense
2,248
2,061
1,938
Losses (gains) on sales of facilities
(37
(14
65,768
87.0
62,080
87.9
57,262
88.1
Income before income taxes
9,832
13.0
8,523
12.1
7,706
11.9
Provision for income taxes
2,050
1,866
1,615
Net income
7,782
10.3
6,657
6,091
Net income attributable to noncontrolling interests
Net income attributable to HCA Healthcare, Inc.
6,784
5,760
5,242
% changes from prior year:
Revenues
Income before income taxes
15.4
10.6
(10.2
Net income attributable to HCA Healthcare, Inc.
17.8
Admissions(a)
Equivalent admissions(b)
Revenue per equivalent admission
Same facility % changes from prior year(c):
Revenues
Admissions(a)
Equivalent admissions(b)
Revenue per equivalent admission
(a)
Represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume.
(b)
Equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenue and gross outpatient revenue and then dividing the resulting amount by gross inpatient revenue. The equivalent admissions computation “equates” outpatient revenue to the volume measure (admissions) used to measure inpatient volume, resulting in a general measure of combined inpatient and outpatient volume.
(c)
Same facility information excludes the operations of hospitals and their related facilities that were either acquired, divested or removed from service during the current and prior year.
HCA HEALTHCARE, INC.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS (Continued)
Results of Operations (continued)
Operating Results Summary (continued)
Operating Data:
Number of hospitals at end of period
Number of freestanding outpatient surgery centers at end of period(a)
Number of licensed beds at end of period(b)
50,436
49,985
49,588
Weighted average beds in service(c)
42,901
42,633
41,873
Admissions(d)
2,297,065
2,236,595
2,130,728
Equivalent admissions(e)
4,107,152

Question: What was HCA Healthcare, Inc.'s revenue in fiscal year 2025?

what was hca healthcare inc.'s revenue in fiscal year 2025?

hca healthcare inc. management's discussion and analysis of financial condition and results of operations (continued) results of operations (continued) operating results summary the following are comparative summaries of operating results and certain operating data for the years ended december 31 2025 2024 and 2023 (dollars in millions): amount ratio amount ratio amount ratio revenues 75600 100.0 70603 100.0 64968 100.0 salaries and benefits 32859 43.5 31170 44.1 29487 45.4 supplies 11367 15.0 10755 15.2 9902 15.2 other operating expenses 15886 21.0 14819 21.0 12875 19.8 equity in earnings of affiliates (78 (23 (22 depreciation and amortization 3523 3312 3077 interest expense 2248 2061 1938 losses (gains) on sales of facilities (37 (14 65768 87.0 62080 87.9 57262 88.1 income before income taxes 9832 13.0 8523 12.1 7706 11.9 provision for income taxes 2050 1866 1615 net income 7782 10.3 6657 6091 net income attributable to noncontrolling interests net income attributable to hca healthcare inc. 6784 5760 5242 % changes from prior year: revenues income before income taxes 15.4 10.6 (10.2 net income attributable to hca healthcare inc. 17.8 admissions(a) equivalent admissions(b) revenue per equivalent admission same facility % changes from prior year(c): revenues admissions(a) equivalent admissions(b) revenue per equivalent admission (a) represents the total number of patients admitted to our hospitals and is used by management and certain investors as a general measure of inpatient volume. (b) equivalent admissions are used by management and certain investors as a general measure of combined inpatient and outpatient volume. equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenue and gross outpatient revenue and then dividing the resulting amount by gross inpatient revenue. the equivalent admissions computation “equates” outpatient revenue to the volume measure (admissions) used to measure inpatient volume resulting in a general measure of combined inpatient and outpatient volume. (c) same facility information excludes the operations of hospitals and their related facilities that were either acquired divested or removed from service during the current and prior year. hca healthcare inc. management's discussion and analysis of financial condition and results of operations (continued) results of operations (continued) operating results summary (continued) operating data: number of hospitals at end of period number of freestanding outpatient surgery centers at end of period(a) number of licensed beds at end of period(b) 50436 49985 49588 weighted average beds in service(c) 42901 42633 41873 admissions(d) 2297065 2236595 2130728 equivalent admissions(e) 4107152


DECEMBER 31, 2025 AND 2024
(Dollars in millions)
ASSETS
Current assets:
Cash and cash equivalents
1,040
1,933
Accounts receivable
10,867
10,751
Inventories
1,652
1,738
Other
2,224
1,992
15,783
16,414
Property and equipment, at cost:
Land
3,415
3,295
Buildings
23,726
22,691
Equipment
36,989
34,670
Construction in progress
2,145
1,858
66,275
62,514
Accumulated depreciation
35,134
33,100
31,141
29,414
Investments of insurance subsidiaries
Investments in and advances to affiliates
Goodwill and other intangible assets
10,293
10,093
Right-of-use operating lease assets
2,130
2,131
Other
60,720
59,513
LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Accounts payable
4,659
4,276
Accrued salaries
2,525
2,304
Other accrued expenses
4,277
3,899
Short-term borrowings and long-term debt due within one year
4,889
4,698
16,350
15,177
Long-term debt, less debt issuance costs and discounts of $
and $
41,603
38,333
Professional liability risks
1,466
1,544
Right-of-use operating lease obligations
1,853
1,863
Income taxes and other liabilities
2,219
2,041
Stockholders’ (deficit) equity:
Common stock $
0.01
par; authorized
1,800,000,000
shares;
outstanding
224,605,100
shares — 2025 and
249,981,400
shares — 2024
Accumulated other comprehensive loss
Retained deficit
5,724
2,115
Stockholders’ deficit attributable to HCA Healthcare, Inc.
6,027
2,499
Noncontrolling interests
3,256
3,054
2,771
60,720
59,513
The accompanying notes are an integral part of the consolidated financial statements.
F-
HCA HEALTHCARE, INC.

Question: What was HCA Healthcare, Inc.'s total assets in fiscal year 2025?

what was hca healthcare inc.'s total assets in fiscal year 2025?

december 31 2025 and 2024 (dollars in millions) assets current assets: cash and cash equivalents 1040 1933 accounts receivable 10867 10751 inventories 1652 1738 other 2224 1992 15783 16414 property and equipment at cost: land 3415 3295 buildings 23726 22691 equipment 36989 34670 construction in progress 2145 1858 66275 62514 accumulated depreciation 35134 33100 31141 29414 investments of insurance subsidiaries investments in and advances to affiliates goodwill and other intangible assets 10293 10093 right-of-use operating lease assets 2130 2131 other 60720 59513 liabilities and stockholders' (deficit) equity current liabilities: accounts payable 4659 4276 accrued salaries 2525 2304 other accrued expenses 4277 3899 short-term borrowings and long-term debt due within one year 4889 4698 16350 15177 long-term debt less debt issuance costs and discounts of and 41603 38333 professional liability risks 1466 1544 right-of-use operating lease obligations 1853 1863 income taxes and other liabilities 2219 2041 stockholders' (deficit) equity: common stock 0.01 par; authorized 1800000000 shares; outstanding 224605100 shares — 2025 and 249981400 shares — 2024 accumulated other comprehensive loss retained deficit 5724 2115 stockholders' deficit attributable to hca healthcare inc. 6027 2499 noncontrolling interests 3256 3054 2771 60720 59513 the accompanying notes are an integral part of the consolidated financial statements. f- hca healthcare inc.


Question: What was HCA Healthcare, Inc.'s net margin in fiscal year 2025?

what was hca healthcare inc.'s net margin in fiscal year 2025?


Question: What was HCA Healthcare, Inc.'s operating cash flow margin in fiscal year 2025?

what was hca healthcare inc.'s operating cash flow margin in fiscal year 2025?


Question: By what percentage did HCA Healthcare, Inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did hca healthcare inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did HCA Healthcare, Inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did hca healthcare inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


(In millions)
Fiscal Years Ended
January 30, 2026
January 31, 2025
February 2, 2024
Cash flows from operating activities:
Net earnings
6,654
6,957
7,726
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization
2,194
1,972
1,923
Noncash lease expense
Deferred income taxes
Asset impairment and loss on property - net
Gain on sale of business
Share-based payment expense
Changes in operating assets and liabilities:
Merchandise inventory – net
1,637
Other operating assets
Accounts payable
1,820
Other operating liabilities
2,227
Net cash provided by operating activities
9,864
9,625
8,140
Cash flows from investing activities:
Purchases of investments
1,693
1,286
1,785
Proceeds from sale/maturity of investments
1,658
1,204
1,722
Capital expenditures
2,213
1,927
1,964
Proceeds from sale of property and other long-term assets
Acquisition of businesses - net
10,088
Proceeds from sale of business
Other – net
Net cash used in investing activities
12,264
1,738
1,901
Cash flows from financing activities:
Net change in commercial paper
Net proceeds from issuance of debt
6,974
2,983
Repayment of debt
2,587
Proceeds from issuance of common stock under share-based payment plans
Cash dividend payments
2,636
2,566
2,531
Repurchases of common stock
4,053
6,138
Other – net
Net cash provided by/(used in) financing activities
1,621
7,047
6,666
Net (decrease)/increase in cash and cash equivalents
Cash and cash equivalents, beginning of year
1,761
1,348
Cash and cash equivalents, end of year
1,761
See accompanying notes to consolidated financial statements.

Question: What was Lowe's Companies, Inc.'s net income in fiscal year 2026?

what was lowe's companies inc.'s net income in fiscal year 2026?

what was net income in fiscal year 2026?

(in millions) fiscal years ended january 30 2026 january 31 2025 february 2 2024 cash flows from operating activities: net earnings 6654 6957 7726 adjustments to reconcile net earnings to net cash provided by operating activities: depreciation and amortization 2194 1972 1923 noncash lease expense deferred income taxes asset impairment and loss on property - net gain on sale of business share-based payment expense changes in operating assets and liabilities: merchandise inventory – net 1637 other operating assets accounts payable 1820 other operating liabilities 2227 net cash provided by operating activities 9864 9625 8140 cash flows from investing activities: purchases of investments 1693 1286 1785 proceeds from sale/maturity of investments 1658 1204 1722 capital expenditures 2213 1927 1964 proceeds from sale of property and other long-term assets acquisition of businesses - net 10088 proceeds from sale of business other – net net cash used in investing activities 12264 1738 1901 cash flows from financing activities: net change in commercial paper net proceeds from issuance of debt 6974 2983 repayment of debt 2587 proceeds from issuance of common stock under share-based payment plans cash dividend payments 2636 2566 2531 repurchases of common stock 4053 6138 other – net net cash provided by/(used in) financing activities 1621 7047 6666 net (decrease)/increase in cash and cash equivalents cash and cash equivalents beginning of year 1761 1348 cash and cash equivalents end of year 1761 see accompanying notes to consolidated financial statements.


Question: What was Lowe's Companies, Inc.'s operating cash flow in fiscal year 2026?

net cash provided by used in operating activities

what was lowe's companies inc.'s operating cash flow in fiscal year 2026?

what was operating cash flow in fiscal year 2026?


(In millions, except per share and percentage data)
Fiscal Years Ended
January 30, 2026
January 31, 2025
February 2, 2024
Current Earnings
Amount
% Sales
Amount
% Sales
Amount
% Sales
Net sales
86,286
100.00
83,674
100.00
86,377
100.00
Cost of sales
57,401
66.52
55,797
66.68
57,533
66.61
Gross margin
28,885
33.48
27,877
33.32
28,844
33.39
Expenses:
Selling, general and administrative
16,791
19.46
15,682
18.74
15,570
18.02
Depreciation and amortization
1,941
2.25
1,729
2.07
1,717
1.99
Operating income
10,153
11.77
10,466
12.51
11,557
13.38
Interest – net
1,406
1.63
1,313
1.57
1,382
1.60
Pre-tax earnings
8,747
10.14
9,153
10.94
10,175
11.78
Income tax provision
2,093
2.43
2,196
2.63
2,449
2.83
Net earnings
6,654
7.71
6,957
8.31
7,726
8.95
Basic earnings per common share
11.87
12.25
13.23
Diluted earnings per common share
11.85
12.23
13.20
Lowe’s Companies, Inc.

Question: What was Lowe's Companies, Inc.'s revenue in fiscal year 2026?

revenue from contract with customer excluding assessed tax

what was lowe's companies inc.'s revenue in fiscal year 2026?

(in millions except per share and percentage data) fiscal years ended january 30 2026 january 31 2025 february 2 2024 current earnings amount % sales amount % sales amount % sales net sales 86286 100.00 83674 100.00 86377 100.00 cost of sales 57401 66.52 55797 66.68 57533 66.61 gross margin 28885 33.48 27877 33.32 28844 33.39 expenses: selling general and administrative 16791 19.46 15682 18.74 15570 18.02 depreciation and amortization 1941 2.25 1729 2.07 1717 1.99 operating income 10153 11.77 10466 12.51 11557 13.38 interest – net 1406 1.63 1313 1.57 1382 1.60 pre-tax earnings 8747 10.14 9153 10.94 10175 11.78 income tax provision 2093 2.43 2196 2.63 2449 2.83 net earnings 6654 7.71 6957 8.31 7726 8.95 basic earnings per common share 11.87 12.25 13.23 diluted earnings per common share 11.85 12.23 13.20 lowe's companies inc.


(In millions, except par value)
January 30, 2026
January 31, 2025
Assets
Current assets:
Cash and cash equivalents
1,761
Short-term investments
Receivables - net
1,090
Merchandise inventory - net
17,300
17,409
Other current assets
1,213
Total current assets
20,955
20,358
Property, less accumulated depreciation
18,362
17,649
Operating lease right-of-use assets
4,303
3,738
Long-term investments
Deferred income taxes - net
Goodwill
3,945
Intangible assets - net
5,908
Other assets
Total assets
54,144
43,102
Liabilities and shareholders’ deficit
Current liabilities:
Current maturities of long-term debt
2,431
2,586
Current operating lease liabilities
Accounts payable
9,762
9,290
Accrued compensation and employee benefits
1,285
1,008
Deferred revenue
1,477
1,358
Other current liabilities
3,795
3,952
Total current liabilities
19,463
18,757
Long-term debt, excluding current maturities
37,490
32,901
Noncurrent operating lease liabilities
4,043
3,628
Deferred income taxes - net
1,039
Deferred revenue - Lowe’s protection plans
1,262
1,268
Other liabilities
Total liabilities
64,061
57,333
Commitments and contingencies
Shareholders’ deficit:
Preferred stock – $
par value: Authorized –
million shares; Issued and outstanding –
none
Common stock – $
0.50
par value: Authorized –
billion shares; Issued and outstanding –
million and
million, respectively
Capital in excess of par value
Accumulated deficit
10,839
14,799
Accumulated other comprehensive income
Total shareholders’ deficit
9,917
14,231
Total liabilities and shareholders’ deficit
54,144
43,102
See accompanying notes to consolidated financial statements.
Lowe’s Companies, Inc.

Question: What was Lowe's Companies, Inc.'s total assets in fiscal year 2026?

what was lowe's companies inc.'s total assets in fiscal year 2026?

what was total assets in fiscal year 2026?

(in millions except par value) january 30 2026 january 31 2025 assets current assets: cash and cash equivalents 1761 short-term investments receivables - net 1090 merchandise inventory - net 17300 17409 other current assets 1213 total current assets 20955 20358 property less accumulated depreciation 18362 17649 operating lease right-of-use assets 4303 3738 long-term investments deferred income taxes - net goodwill 3945 intangible assets - net 5908 other assets total assets 54144 43102 liabilities and shareholders' deficit current liabilities: current maturities of long-term debt 2431 2586 current operating lease liabilities accounts payable 9762 9290 accrued compensation and employee benefits 1285 1008 deferred revenue 1477 1358 other current liabilities 3795 3952 total current liabilities 19463 18757 long-term debt excluding current maturities 37490 32901 noncurrent operating lease liabilities 4043 3628 deferred income taxes - net 1039 deferred revenue - lowe's protection plans 1262 1268 other liabilities total liabilities 64061 57333 commitments and contingencies shareholders' deficit: preferred stock – par value: authorized – million shares; issued and outstanding – none common stock – 0.50 par value: authorized – billion shares; issued and outstanding – million and million respectively capital in excess of par value accumulated deficit 10839 14799 accumulated other comprehensive income total shareholders' deficit 9917 14231 total liabilities and shareholders' deficit 54144 43102 see accompanying notes to consolidated financial statements. lowe's companies inc.


Question: What was Lowe's Companies, Inc.'s gross margin in fiscal year 2026?

what was lowe's companies inc.'s gross margin in fiscal year 2026?


Question: What was Lowe's Companies, Inc.'s net margin in fiscal year 2026?

what was lowe's companies inc.'s net margin in fiscal year 2026?


Question: What was Lowe's Companies, Inc.'s operating cash flow margin in fiscal year 2026?

what was lowe's companies inc.'s operating cash flow margin in fiscal year 2026?


Question: By what percentage did Lowe's Companies, Inc.'s net income change from fiscal year 2025 to fiscal year 2026?

by what percentage did lowe's companies inc.'s net income change from fiscal year 2025 to fiscal year 2026?

by what percentage did net income change from fiscal year 2025 to fiscal year 2026?


Question: By what percentage did Lowe's Companies, Inc.'s operating income change from fiscal year 2025 to fiscal year 2026?

by what percentage did lowe's companies inc.'s operating income change from fiscal year 2025 to fiscal year 2026?

by what percentage did operating income change from fiscal year 2025 to fiscal year 2026?


Question: By what percentage did Lowe's Companies, Inc.'s revenue change from fiscal year 2025 to fiscal year 2026?

by what percentage did lowe's companies inc.'s revenue change from fiscal year 2025 to fiscal year 2026?

by what percentage did revenue change from fiscal year 2025 to fiscal year 2026?


Consolidated Statements of Comprehensive Income

Fiscal Years Ended January 31,
(Amounts in millions)
Consolidated net income
22,270
20,157
16,270
Consolidated net income attributable to noncontrolling interest
Consolidated net income attributable to Walmart
21,893
19,436
15,511
Other comprehensive income (loss), net of income taxes
1,009
2,859
Other comprehensive (income) loss attributable to noncontrolling interest
Other comprehensive income (loss) attributable to Walmart
2,303
Comprehensive income, net of income taxes
23,279
17,298
17,214
Comprehensive income attributable to noncontrolling interest
1,325
Comprehensive income attributable to Walmart
22,728
17,133
15,889
See accompanying notes.
Walmart Inc.

Question: What was Walmart Inc.'s net income in fiscal year 2026?

what was net income in fiscal year 2026?

what was walmart inc.'s net income in fiscal year 2026?

fiscal years ended january 31 (amounts in millions) consolidated net income 22270 20157 16270 consolidated net income attributable to noncontrolling interest consolidated net income attributable to walmart 21893 19436 15511 other comprehensive income (loss) net of income taxes 1009 2859 other comprehensive (income) loss attributable to noncontrolling interest other comprehensive income (loss) attributable to walmart 2303 comprehensive income net of income taxes 23279 17298 17214 comprehensive income attributable to noncontrolling interest 1325 comprehensive income attributable to walmart 22728 17133 15889 see accompanying notes. walmart inc.


Fiscal Years Ended January 31,
(Amounts in millions)
Cash flows from operating activities:
Consolidated net income
22,270
20,157
16,270
Adjustments to reconcile consolidated net income to net cash provided by operating activities:
Depreciation and amortization
14,203
12,973
11,853
Investment (gains) and losses, net
2,016
3,193
Deferred income taxes
2,277
Other operating activities
4,079
2,889
2,642
Changes in certain assets and liabilities, net of effects of acquisitions and dispositions:
Receivables, net
1,136
1,106
Inventories
1,443
2,755
2,017
Accounts payable
1,611
3,228
2,515
Accrued liabilities
1,607
1,324
Accrued income taxes
Net cash provided by operating activities
41,565
36,443
35,726
Cash flows from investing activities:
Payments for property and equipment
26,642
23,783
20,606
Proceeds from the disposal of property and equipment
Proceeds from disposal of certain strategic investments
4,080
Payments for business acquisitions, net of cash acquired
1,896
Other investing activities
Net cash used in investing activities
26,350
21,379
21,287
Cash flows from financing activities:
Net change in short-term borrowings
3,523
2,212
Proceeds from issuance of long-term debt
3,983
4,967
Repayments of long-term debt
2,625
3,468
4,217
Dividends paid
7,507
6,688
6,140
Purchase of Company stock
8,088
4,494
2,779
Dividends paid to noncontrolling interest
Purchase of noncontrolling interest
3,462
Sale of subsidiary stock
Other financing activities
2,511
2,170
2,248
Net cash used in financing activities
13,553
14,822
13,414
Effect of exchange rates on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
1,785
1,094
Cash, cash equivalents and restricted cash at beginning of year
9,536
9,935
8,841
Cash, cash equivalents and restricted cash at end of year
11,321
9,536
9,935
Supplemental disclosure of cash flow information:
Income taxes paid
5,364
5,884
5,879
Interest paid
2,793
2,739
2,519
See accompanying notes.
Walmart Inc.

Question: What was Walmart Inc.'s operating cash flow in fiscal year 2026?

net cash provided by used in operating activities

what was operating cash flow in fiscal year 2026?

what was walmart inc.'s operating cash flow in fiscal year 2026?

fiscal years ended january 31 (amounts in millions) cash flows from operating activities: consolidated net income 22270 20157 16270 adjustments to reconcile consolidated net income to net cash provided by operating activities: depreciation and amortization 14203 12973 11853 investment (gains) and losses net 2016 3193 deferred income taxes 2277 other operating activities 4079 2889 2642 changes in certain assets and liabilities net of effects of acquisitions and dispositions: receivables net 1136 1106 inventories 1443 2755 2017 accounts payable 1611 3228 2515 accrued liabilities 1607 1324 accrued income taxes net cash provided by operating activities 41565 36443 35726 cash flows from investing activities: payments for property and equipment 26642 23783 20606 proceeds from the disposal of property and equipment proceeds from disposal of certain strategic investments 4080 payments for business acquisitions net of cash acquired 1896 other investing activities net cash used in investing activities 26350 21379 21287 cash flows from financing activities: net change in short-term borrowings 3523 2212 proceeds from issuance of long-term debt 3983 4967 repayments of long-term debt 2625 3468 4217 dividends paid 7507 6688 6140 purchase of company stock 8088 4494 2779 dividends paid to noncontrolling interest purchase of noncontrolling interest 3462 sale of subsidiary stock other financing activities 2511 2170 2248 net cash used in financing activities 13553 14822 13414 effect of exchange rates on cash cash equivalents and restricted cash net increase (decrease) in cash cash equivalents and restricted cash 1785 1094 cash cash equivalents and restricted cash at beginning of year 9536 9935 8841 cash cash equivalents and restricted cash at end of year 11321 9536 9935 supplemental disclosure of cash flow information: income taxes paid 5364 5884 5879 interest paid 2793 2739 2519 see accompanying notes. walmart inc.